Inabata Inabata

X
[{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Lakewood-Amedex"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Promore Pharma"},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Microbion"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with M\u00f6lnlycke on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Molnlycke Health Care AB"},{"orgOrder":0,"company":"3M Health Care","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with 3M on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"3M Health Care"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Topline Results from its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"orgOrder":0,"company":"Discovery Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Discovery Therapeutics Caribe Receives Study May Proceed Letter from FDA to Initiate a Phase 3 Clinical Trial of Intralesional rhEGF for the Treatment of Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery Therapeutics"},{"orgOrder":0,"company":"Rion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RION Announces First Patient Dosed in Phase 2 Clinical Study of Purified Exosome Product\u2122 for Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Rion"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            Purified Exosome Product, designed to promote cell growth and formation of new blood vessels, while also reducing inflammation and protecting cells, is being investigated for diabetic foot ulcer.

            Lead Product(s): Purified Exosome-based Therapy

            Therapeutic Area: Podiatry Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 07, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            rhEGF (recombinant human epidermal growth factor) is a 53 amino acid polypeptide isolated for the first time from mice submaxillary glands. It is being evaluated for the treatment of complex and complicated refractory neuropathic, ischemic, and neuroischemic diabetic foot ulcers.

            Lead Product(s): Recombinant Human Epidermal Growth Factor

            Therapeutic Area: Podiatry Product Name: rhEGF

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 30, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            EscharEx (EX-02) is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During debridement phase, 3M’s two-layer compression systems will be used as soc in all study arms, until the wounds reach complete healing.

            Lead Product(s): EX-02

            Therapeutic Area: Podiatry Product Name: EscharEx

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: MediWound

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 11, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration, Mölnlycke will provide Mepilex® Up, its most recent line extension to its global market leading brand, along with Exufiber® and Exufiber® Ag dressings to be used during MediWound's upcoming Phase III study of EscharEx (EX-02) in venous leg ulcers.

            Lead Product(s): EX-02

            Therapeutic Area: Podiatry Product Name: EscharEx

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: MediWound

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            EscharEx is a topical bioactive therapy for debridement of chronic and other hard-to-heal wounds is a product candidate in advanced stages of development.

            Lead Product(s): EX-02

            Therapeutic Area: Podiatry Product Name: EscharEx

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            MBN-101 (pravibismane) is the first in a new class of anti-infective drugs demonstrating broad-spectrum potency against a wide range of multidrug-resistant bacteria, and biofilms ubiquitous in DFU infections.

            Lead Product(s): Pravibismane

            Therapeutic Area: Podiatry Product Name: MBN-101

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The most important finding from that clinical trial was that ropocamptide (LL-37) shows a significant effect in the patient subgroup with large wounds (≥10 cm2).

            Lead Product(s): Ropocamptide

            Therapeutic Area: Podiatry Product Name: LL-37

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            EscharEx (proteolytic enzymes enriched bromelain) is a bioactive therapy for debridement of chronic and other hard-to-heal wounds in advanced stages of clinical development, is easy-to-use concentrate of proteolytic enzymes enriched in bromelain for topical daily applications.

            Lead Product(s): Bromelain Enriched Proteolytic Enzyme

            Therapeutic Area: Podiatry Product Name: EscharEx

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Bisphosphocins are novel small protonated nucleotide derivative molecules that exert their antibacterial activity by depolarization and rupture of the bacterial cell membranes, causing rapid bacterial cell death.

            Lead Product(s): Bisphosphocin

            Therapeutic Area: Podiatry Product Name: Nu-3

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 05, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            EscharEx (EX-02) is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During debridement phase, 3M’s two-layer compression systems will be used as soc in all study arms, until the wounds reach complete healing.

            Lead Product(s): Bromelain Enriched Proteolytic Enzyme

            Therapeutic Area: Podiatry Product Name: EscharEx

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 24, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY